Integration with growth hormone pathways Many body composition protocols incorporate growth hormone secretagogues or fragments
Retatrutide is an unapproved investigational triple agonist (GLP-1, GIP, glucagon receptors) not licensed by the MHRA, EMA, or FDA for routine clinical use
For the older patients (60+ years) specially with arteriosclerosis, possibility of circulatory collapse after administration should be kept in mind (30)
[1] [2] As of 20242025, retatrutide remains under clinical investigation and has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, nor by the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA) for routine clinical use
Protocol modifications for CAI typically involve longer durations than acute injury protocols
This is also why injecting glutathione subcutaneously is the easiest means of administering the peptide in adequate doses, albeit multiple injections are required to achieve therapeutic levels of GSH support